Abstract
Pharmacogenomics (PGx) and biomarkers have gradually been recognized as useful tools for use throughout the life cycle of a drug or device, from development through post-approval activities. In September 2005, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) established the PGx Discussion Group (PDG) to appropriately manage PGx issues in Japan’s regulatory process. The PDG only covered PGx issues, but recently, interest in other ‘omics’ areas, such as proteomics, metabonomics and metabolomics have rapidly increased. Therefore, in April 2009, the PDG was re-organized as the PMDA Omics Project (POP), which covers not only PGx but also proteomics, metabonomics, metabolomics and related issues.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The Path from Biomarker Discovery to Regulatory Qualification
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.